<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05026710</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00199486</org_study_id>
    <nct_id>NCT05026710</nct_id>
  </id_info>
  <brief_title>Better Lithotripsy and Ureteroscopy Evaluation of Stenting (BLUES)</brief_title>
  <acronym>BLUES</acronym>
  <official_title>Better Lithotripsy and Ureteroscopy Evaluation of Stenting (BLUES) A Pragmatic Randomized Multi-center Comparative Effectiveness Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center trial is being completed to compare patient outcomes related to the Imajin&#xD;
      silicone stent in comparison to non-silicone polyurethane stents after ureteroscopy.&#xD;
&#xD;
      Eligible participants will be enrolled and randomly assigned to receive the Imajin silicone&#xD;
      stent or a non-silicone stent. In addition, the participants will complete questionnaires and&#xD;
      have follow-up information collected (approximately 60 days after surgery).&#xD;
&#xD;
      The trial hypothesizes that a ureteral stent made of silicone, will have superior outcomes&#xD;
      when compared to non-silicone stents.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) scores of pain-intensity at 7 to 10 days</measure>
    <time_frame>Baseline, 7 to 10 days</time_frame>
    <description>This is a 3-item survey which participants select a response for intensity of their pain (no pain-very severe). Scores range from 36.3 - 81.8 with 81.8 being worse.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) scores of pain-interference at 7 to 10 days</measure>
    <time_frame>Baseline, 7 to 10 days</time_frame>
    <description>This is a a 6-item survey in which participants respond how much pain interfered with their life (not at all- very much). Scores range from 41 - 78.3 with 78.3 being worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) scores of pain-intensity at 4 to 6 weeks</measure>
    <time_frame>Baseline, 4 to 6 weeks</time_frame>
    <description>This is a 3-item survey which participants select a response for intensity of their pain (no pain-very severe). Scores range from 36.3 - 81.8 with 81.8 being worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) scores of pain-interference at 4 to 6 weeks</measure>
    <time_frame>Baseline, 4 to 6 weeks</time_frame>
    <description>This is a a 6-item survey in which participants respond how much pain interfered with their life (not at all- very much). Scores range from 41 - 78.3 with 78.3 being worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in National Institutes of Health (NIH) Lower Urinary Tract Dysfunction Research Network (LURN) Symptoms Index (SI)-10 scores at 7 to 10 days</measure>
    <time_frame>baseline, 7 to10 days</time_frame>
    <description>The LURN SI-10 (10-Item LURN Symptom Index) assesses urinary frequency, nocturia, urgency, incontinence, bladder pain, voiding and post-micturition symptoms. Scores ranging from 0 to 38 (higher scores = worse symptoms/bother).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NIH LURN SI-10 scores at 4 to 6 weeks</measure>
    <time_frame>Baseline, 4 to 6 weeks</time_frame>
    <description>The LURN SI-10 (10-Item LURN Symptom Index) assesses urinary frequency, nocturia, urgency, incontinence, bladder pain, voiding and post-micturition symptoms. Scores ranging from 0 to 38 (higher scores = worse symptoms/bother).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite healthcare utilization metric within 30 days</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Hospitalization and intensive care unit care&#xD;
Unplanned hospitalization&#xD;
Emergency department visit&#xD;
Ambulatory encounter: Clinic visit&#xD;
Ambulatory encounter: Phone call or message</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal imaging findings within 60 days</measure>
    <time_frame>up to 60 days</time_frame>
    <description>New or worsening hydronephrosis, hematoma, and/or urinoma of the operative renal unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stone-free rates within 60 days</measure>
    <time_frame>up to 60 days</time_frame>
    <description>No residual stone of the treated stone by postoperative imaging (CT, US, X-Ray, or any combination).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Renal Stone</condition>
  <condition>Ureteral Stone</condition>
  <arm_group>
    <arm_group_label>Silicone (Coloplast Imajin Hydro) ureteral stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer).</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Silicone (Coloplast Imajin Hydro) ureteral stent</intervention_name>
    <description>During the end of the standard of care ureteroscopy the silicone stent will be placed.</description>
    <arm_group_label>Silicone (Coloplast Imajin Hydro) ureteral stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer)</intervention_name>
    <description>During the end of the standard of care ureteroscopy the Non-silicone (Polyurethane/Percuflex) stent will be placed.</description>
    <arm_group_label>Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer).</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Diagnosed with unilateral renal and/or ureteral stones with the largest less than or&#xD;
             equal to (≤)2.0 cm in size measured on abdominal x-ray, Ultrasound or computerized&#xD;
             tomography (CT) scan&#xD;
&#xD;
               -  Renal stone defined as only renal location of stone(s).&#xD;
&#xD;
               -  Ureteral stone defined as ureteral only or ureteral and renal stone(s).&#xD;
&#xD;
          -  Planned unilateral ureteroscopy with stent placement without stent string.&#xD;
&#xD;
          -  Ability to take oral medication.&#xD;
&#xD;
          -  Ability and willingness to complete and adhere to survey questions and responses&#xD;
             throughout study duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known planned secondary or staged procedure&#xD;
&#xD;
          -  Presence of anatomical anomalies (for example (e.g.) solitary, horseshoe, fused&#xD;
             crossed ectopia, pelvic kidney)&#xD;
&#xD;
          -  Presence of any prior urinary diversion (e.g. ileal conduit, orthotopic neobladder)&#xD;
&#xD;
          -  Presence of any indwelling ureteral stent prior to ureteroscopy&#xD;
&#xD;
          -  Presence of any indwelling nephrostomy tube prior to ureteroscopy&#xD;
&#xD;
          -  Ancillary ureteroscopy to treat residual fragments after percutaneous renal stone&#xD;
             surgery&#xD;
&#xD;
          -  Renal stone located in calyceal diverticulum&#xD;
&#xD;
          -  No indication for stent placement (e.g. spontaneous passage)&#xD;
&#xD;
          -  Bladder stone location.&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Known allergic reactions to polyurethane or silicone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khurshid Ghani, MD, MS, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khurshid Ghani, MD, MS, FRCS</last_name>
    <phone>734-763-2797</phone>
    <email>kghani@med.umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Michigan Medicine</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Khurshid Ghani, MD, MS, FRCS</last_name>
      <phone>734-763-2797</phone>
      <email>kghani@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Khurshid Ghani, MD, MS, FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Medicine</name>
      <address>
        <city>Brighton</city>
        <state>Michigan</state>
        <zip>48116</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Khurshid Ghani, MD, MS, FRCS</last_name>
      <phone>734-763-2797</phone>
      <email>kghani@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Khurshid Ghani, MD, MS, FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chelsea Hospital (Saint Joseph Mercy)</name>
      <address>
        <city>Chelsea</city>
        <state>Michigan</state>
        <zip>48118</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Casey Dauw, MD</last_name>
      <phone>630-842-9558</phone>
      <email>caseydau@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Casey Dauw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Leavitt, MD</last_name>
      <phone>313-916-1941</phone>
      <email>dleavit1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>David Leavitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49456</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hector Pimentel, MD</last_name>
      <phone>616-258-4010</phone>
      <email>hpimente100@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hector Pimentel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension Hospital (Comprehensive Urology)</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48374</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Wenzler, MD</last_name>
      <phone>248-569-4897</phone>
      <email>DWenzler@urologist.org</email>
    </contact>
    <investigator>
      <last_name>David Wenzler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital (Michigan Institute of Urology)</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Brian Seifman, MD</last_name>
      <phone>248-293-9701</phone>
      <email>seifmanb@michiganurology.com</email>
    </contact>
    <investigator>
      <last_name>Brian Seifman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital (Michigan Institute of Urology)</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Brian Seifman, MD</last_name>
      <phone>248-293-9701</phone>
      <email>seifmanb@michiganurology.com</email>
    </contact>
    <investigator>
      <last_name>Brian Seifman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Wyandotte Hospital</name>
      <address>
        <city>Wyandotte</city>
        <state>Michigan</state>
        <zip>48192</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Naveen Kachroo, MD</last_name>
      <phone>734-287-9399</phone>
      <email>NKACHRO1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Naveen Kachroo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrated Healthcare Association (IHA) (Saint Joseph Mercy Hospital)</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Eduardo Kleer, MD</last_name>
      <phone>734-649-1207</phone>
      <email>Eduardo_Kleer@ihacares.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo Kleer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Khurshid Ghani</investigator_full_name>
    <investigator_title>Associate Professor of Urology</investigator_title>
  </responsible_party>
  <keyword>Ureteral stent</keyword>
  <keyword>Ureteroscopy</keyword>
  <keyword>Lithotripsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

